Merck KGaA (FRA:MRK) has been given a €103.00 ($119.77) target price by analysts at Independent Research GmbH in a research note issued to investors on Thursday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Independent Research GmbH’s price target would indicate a potential upside of 14.71% from the company’s current price.
Several other equities analysts also recently issued reports on MRK. DZ Bank AG reissued a “sell” rating on shares of Merck KGaA in a report on Tuesday, July 18th. Berenberg Bank set a €110.00 ($127.91) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, July 26th. J P Morgan Chase & Co set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, July 26th. Deutsche Bank AG set a €106.00 ($123.26) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, July 26th. Finally, Credit Suisse Group set a €106.00 ($123.26) price target on shares of Merck KGaA and gave the company a “neutral” rating in a report on Wednesday, July 26th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of €108.61 ($126.29).
Shares of Merck KGaA (FRA:MRK) traded down €1.72 ($2.00) on Thursday, hitting €89.79 ($104.41). 952,135 shares of the stock traded hands. Merck KGaA has a 52 week low of €89.00 ($103.49) and a 52 week high of €115.00 ($133.72).
COPYRIGHT VIOLATION NOTICE: “Merck KGaA (MRK) Given a €103.00 Price Target by Independent Research GmbH Analysts” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2017/11/11/merck-kgaa-mrk-given-a-103-00-price-target-by-independent-research-gmbh-analysts.html.
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.